Read Larry Connors' blog – Short Term Trading Strategies
This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.
Scope
- Details of development stage by sector and equipment type.
- Pipeline products grouped by therapy area, development stage and trial phase.
- Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
- Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
- Product updates covering estimated approval dates and estimated launch dates.
- Descriptions of novel technologies relating to pipeline products of the company.
- Patents and patent applications covered for the product.
- News updates on key events relating to the product and its development.
Reasons to buy
- A single source to fulfil competitor information relating to products in development.
- Identify pipeline products that are potential competitor to your product lines.
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
- Access clinical trial information to map trial results and plan targeted marketing activities.
- Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
- Identification of potential investment opportunities.
- Build up knowledge base for potential distribution and marketing partners.
- Helps avoid patent infringement.
- Timelines from concept to market lets you keep track of market potential build for a new product.
- Assess a companys future growth by determining its pipeline depth, for probable acquisition opportunities.
Key Topics Covered:
- Executive Summary
- Company Overview
- Cardima, Inc. Pipeline Products
- REVELATION Tx
- Therastream
- Revelation Helix STX
- Revelation Helix
- Recent Developments
- 4.1 Product News
- 4.1.1 Sep 02, 2008: Cardima Completes First Successful Cases In Thailand And Commences Training Program With Dr. Li Poa
- 4.1.2 Jun 30, 2008: Cardima Receives Chinese SFDA Approval To Market The INTELLITEMP Energy Management Device In The Peoples Republic Of China
- 4.1.3 Oct 11, 2007: Cardima Announces Patent For INTELLITEMP Energy Management Device
- 4.1.4 Jun 15, 2005: Cardima Inc. Meets With FDA Regarding Revelation TX PMA
- 4.1.5 May 28, 2004: Cardima Receives Non-Approvable Letter From FDA For REVELATION Tx
- 4.1.6 Mar 16, 2004: Cardima Reports On First Clinical Use Of Its INTELLITEMP Radio Frequency Energy Management Device For Pulmonary Vein Isolation
- 4.1.7 Jul 10, 2003: Cardima Receives Approval To Sell New Configuration Microcatheter In Europe; REVELATION Helix STX Extends Treatment Range For Pulmonary Vein Therapeutic Product Line
- 4.1.8 Jul 07, 2003: Revelation Tx Microcatheter Maze Procedure Successfully Treats Paroxysmal AF
- 4.1.9 Nov 05, 2002: Cardima REVELATION Tx Granted Expedited Review By The FDA
- 4.1.10 Apr 03, 2001: FDA Allows Modular PMA Filing For The Revelation Tx System; Cardima Files First Module Of Premarket Approval Application
- 4.1.11 Dec 04, 1998: Cardima Receives Approval For The Revelation Tx To Treat Atrial Fibrillation In The European Union
- Product Approvals
- Jun 30, 2008: Cardima Receives Chinese SFDA Approval To Market The INTELLITEMP Energy Management Device In The Peoples Republic Of China
- Jul 10, 2003: Cardima Receives Approval To Sell New Configuration Microcatheter In Europe; REVELATION Helix STX Extends Treatment Range For Pulmonary Vein Therapeutic Product Line
- Dec 04, 1998: Cardima Receives Approval For The Revelation Tx To Treat Atrial Fibrillation In The European Union - Clinical Trials
- Mar 16, 2004: Cardima Reports On First Clinical Use Of Its INTELLITEMP Radio Frequency Energy Management Device For Pulmonary Vein Isolation
- Jul 07, 2003: Revelation Tx Microcatheter Maze Procedure Successfully Treats Paroxysmal AF - Appendix
- List of Figures
For more information visit http://www.researchandmarkets.com/research/e5243f/cardima_inc_prod
CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (US) Fax: +353 1 481 1716 (Rest of World) e-mail: press@researchandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
